RxDoctor Payments Data

John Simmons, MD

General Practice · Linden, ALNPI 1104832724

Payments from drug & device makers

$1,107in general payments, 2019–2025

Across 68 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$398
  • Lilly USA, LLC$302
  • Sunovion Pharmaceuticals Inc.$84
  • AstraZeneca$61
  • Pfizer$52
  • AbbVie$51
  • plus $160 from 7 others

What the payments were for

  • Food & beverage$1,09899%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,107 in reported general payments places this provider in the 80th percentile of 1,114 general practice providers in Alabama.

See all general practice providers in Alabama

Medicare billing

Part B allowed, 2024
$113,996
Medicare patients
168
Services billed
3,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide174$186,933
OzempicSemaglutide126$120,895
EliquisApixaban185$112,327
RybelsusSemaglutide40$62,209
LinzessLinaclotide72$50,233
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl153$49,279
TrulicityDulaglutide35$42,270
GemtesaVibegron51$39,324
XareltoRivaroxaban98$38,003
FarxigaDapagliflozin Propanediol42$35,681
JardianceEmpagliflozin31$35,334
Tresiba Flextouch U-200Insulin Degludec35$30,819
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$29,702
JanuviaSitagliptin Phosphate33$27,068
EntrestoSacubitril/Valsartan53$26,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$302$229,203209 claims
Novo NordiskOzempic, Rybelsus$398$183,104166 claims
PfizerEliquis$52$112,327185 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$61$71,267104 claims
Johnson & JohnsonXarelto, Invokana$35$51,665114 claims
AbbVieLinzess$51$50,23372 claims
Sumitomo Pharma America, Inc.Gemtesa$26$39,32451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,114 general practice providers in Alabama.

Other general practice in Linden

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →